UCB and Biogen announced positive Phase 3 trial results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus (SLE). The drug, combined with standard care, significantly improved disease activity at 48 weeks compared to placebo, including reducing severe flares and fatigue. It also helped patients reduce glucocorticoid steroid doses, indicating a steroid-sparing effect. The drug showed a favorable safety profile, supporting ongoing Phase 3 confirmatory trials.
The Gross Law Firm has announced an investigation into possible securities fraud involving Biogen Inc. Investors who suffered losses on Biogen stock are encouraged to contact the firm to discuss their legal rights. The firm alleges that misleading st...
Biogen is under investigation by Pomerantz LLP for possible securities fraud following the release of Phase 2 trial results for its Alzheimer's drug candidate diranersen. Although Biogen called the results "compelling," the trial failed to meet its p...
